Article Text
Unexpected outcome (positive or negative) including adverse drug reactions
CASE REPORT
Abciximab-induced delayed profound thrombocytopaenia
Summary
Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary intervention of left anterior descending artery and was eventually diagnosed with abciximab-induced delayed thrombocytopaenia. This case outlines the importance of close follow-up of these patients to prevent serious adverse events.
- Cardiovascular system
- Safety
- Unwanted effects / adverse reactions